Pharmacy- Page 53

Roche ranked the most sustainable healthcare company in the DJSI

November 16, 2020

Pharmacy

The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as a benchmark for investors who integrate sustainability considerations into their portfolios. Roche has

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results

by The FINANCIAL

November 16, 2020

2 mins read

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

The FINANCIAL — Metagenomi, a next generation gene editing company launched by

by The FINANCIAL

November 12, 2020

1 min read

Pharmaceutical industries join to promise fair access to COVID-19 medicines and vaccines

The FINANCIAL — On the occasion of the World Health Assembly, the world’s

by The FINANCIAL

November 12, 2020

1 min read

Pharmacy

Sanofi Appoints Dr. Yong-Jun Liu as Head of Research

The FINANCIAL -- Sanofi announced on March 29 the appointment of Dr. Yong-Jun Liu as Head of Research, Global R&D, effective April 1, 2016. He will report to Dr. Elias Zerhouni, President, Global R&D.

by The FINANCIAL

March 29, 2016

1 min read

Pharmacy

Novo Nordisk breaks ground on USD 2bn production facility in Clayton, North Carolina

The FINANCIAL -- On March 28, Novo Nordisk broke ground on its new 2 billion US dollar production facility in Clayton, North Carolina.

by The FINANCIAL

March 29, 2016

1 min read

Pharmacy

GSK receives marketing authorisation for Nucala (mepolizumab) in Japan

The FINANCIAL -- GlaxoSmithKline plc on March 29 announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for Nucala (mepolizumab) as a treatment for bronchial asthma in patients with refractory asthma whose symptoms are inadequately controlled with

by The FINANCIAL

March 29, 2016

1 min read

Pharmacy

AstraZeneca: Japan Approves Tagrisso For EGFR T790M Mutation-positive Cancer

The FINANCIAL -- AstraZeneca on March 29 announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Tagrisso (osimertinib, AZD9291) 80mg once-daily tablets for the treatment of patients with epidermal growth factor receptor (EGFR) T790M mutation-positive inoperable or recurrent

by The FINANCIAL

March 29, 2016

2 mins read

Pharmacy

Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc.

The FINANCIAL -- Bristol-Myers Squibb Company and Padlock Therapeutics, Inc. announced on March 23 that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Padlock, a private, Cambridge, Massachusetts-based biotechnology company

by The FINANCIAL

March 23, 2016

1 min read

Pharmacy

Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Praluent Study in Patients Undergoing LDL Apheresis Therapy

The FINANCIAL -- Sanofi and Regeneron Pharmaceuticals, Inc. on March 23 announced positive results from the Phase 3 ODYSSEY ESCAPE trial evaluating Praluent (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH), whose cholesterol

by The FINANCIAL

March 23, 2016

1 min read

Pharmacy

Dr. Michael Preuss to be new head of Communications at Bayer

The FINANCIAL -- Effective May 1, 2016, Dr. Michael Preuss (42) will become head of Communications, Government Relations and Corporate Brand at Bayer AG. This organizational unit covers the company’s internal, external and digital communications, and has responsibility for political communication activities

by The FINANCIAL

March 23, 2016

1 min read

Pharmacy

Lilly’s Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis

The FINANCIAL -- Eli Lilly and Company announced on March 22 that the U.S. Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy

by The FINANCIAL

March 23, 2016

4 mins read

Pharmacy

AstraZeneca reports top-line results from the Brilinta SOCRATES trial in stroke

The FINANCIAL -- AstraZeneca on March 23 announced the top-line results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique (ticagrelor) 90mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack

by The FINANCIAL

March 23, 2016

1 min read

Pharmacy

Allergan Receives Complete Response Letter from FDA for Prior Approval Supplement for RESTASIS 0.05% Multi-Dose Preservative-Free Bottle

The FINANCIAL -- Allergan plc announced on March 10 it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its Prior Approval Supplement (PAS) for RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05%, Multi-Dose Preservative-Free (MDPF) presentation.

by The FINANCIAL

March 11, 2016

1 min read